ArticleTranslational oncology2019
Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer.
Article in Translational oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Oxaliplatin and 5-FU Based Preoperative Chemoradiation
Functional MRI of Hypoxia-mediated Rectal Cancer Aggressiveness
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Prognostic value of extracellular vesicles in colorectal cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Pooled it
- Tumour-derived exosomes in liver metastasis: A Pandora's box.Cell proliferation · 2023Pooled it
- MiR-375 in CAFs-Derived EVs Promotes HCC Progression via Regulating RASA1 and May Potentially Serve as a Biomarker for HCC.Cancer science · 2026Article
- Patterns of miRNA Expression in Primary and Metastatic Wilms Tumor.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Regulatory roles of microRNAs in signaling pathways and their biomarker potential in prostate cancer.Cancer cell international · 2026Review
- Colorectal cancer liver metastases: mechanism and therapy.Frontiers in immunology · 2026Review
- Enhanced Early Detection of Colorectal Cancer via Blood Biomarker Combinations Identified Through Extracellular Vesicle Isolation and Artificial Intelligence Analysis.Journal of extracellular vesicles · 2025Article
- Extracellular vesicles in cancer´s communication: messages we can read and how to answer.Molecular cancer · 2025Review
- TLN1: an oncogene associated with tumorigenesis and progression.Discover oncology · 2024Review
- Recent Technologies towards Diagnostic and Therapeutic Applications of Circulating Nucleic Acids in Colorectal Cancers.International journal of molecular sciences · 2024Review
- Cancer-derived exosomes as novel biomarkers in metastatic gastrointestinal cancer.Molecular cancer · 2024Review
- Emerging role of exosomes as a liquid biopsy tool for diagnosis, prognosis & monitoring treatment response of communicable & non-communicable diseases.The Indian journal of medical research · 2024Review
- [Plasma miRNA expression in patients with genetically confirmed multiple endocrine neoplasia type 1 syndrome and its phenocopies].Problemy endokrinologii · 2024Article
- Tumor-derived small extracellular vesicles in cancer invasion and metastasis: molecular mechanisms, and clinical significance.Molecular cancer · 2024Review
- Review
- Circulating exosomal microRNAs as potential prognostic biomarkers in gastrointestinal cancers: a systematic review and meta-analysis.Cancer cell international · 2023Review
- Exosome-Encapsulated miR-31, miR-192, and miR-375 Serve as Clinical Biomarkers of Gastric Cancer.Journal of oncology · 2023Article
- Liquid biopsies to occult brain metastasis.Molecular cancer · 2022Review
- Exosomal and Non-Exosomal MicroRNAs: New Kids on the Block for Cancer Therapy.International journal of molecular sciences · 2022Review
- Exosome-derived noncoding RNAs: Function, mechanism, and application in tumor angiogenesis.Molecular therapy. Nucleic acids · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As many as 30% to 40% of locally advanced rectal cancer (LARC) patients experience metastatic progression of the disease. Recognizing the potential of the genetic cargo in tumor-derived exosomes, we hypothesized that plasma exosomal microRNA (miRNA) may reflect biological aggressiveness in LARC and provide new markers for rectal cancer aggressiveness and risk stratification. In a prospective LARC cohort (NCT01816607), plasma samples were collected from 29 patients at the time of diagnosis, before neoadjuvant therapy and surgery. Exosomes, precipitated from plasma using a commercial kit, were verified by cryo-electron microscopy, nanoparticle tracking analysis, and western blotting. Expression of exosomal miRNAs was profiled using a miRCURY LNA miRNA microarray and validation of six miRNAs associated with pathological and clinical end-points was undertaken in plasma collected at the time of diagnosis from 64 patients in an independent prospective LARC cohort (NCT00278694). In both cohorts, exosomal miR-141-3p and miR-375 were higher in patients with synchronous liver metastasis than in those without (P = .010 and P = .017 respectively in the investigative cohort, and P < .001 for both in the validation cohort). Further, high exosomal miR-141-3p was associated with post-operative metastatic liver progression in the investigative cohort (P = .034). Because both miRNAs are associated with tumor angiogenesis and immune modulation, we propose that these miRNAs in circulating exosomes may reflect rectal cancer aggressiveness and accordingly be candidate biomarkers for further investigations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.